Monthly Archives: December 2018

MOLECULAR PARTNERS AND AMGEN ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY

By | Uncategorized | No Comments

Molecular Partners and Amgen announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).

Read More